<DOC>
	<DOCNO>NCT00430716</DOCNO>
	<brief_summary>To demonstrate dose response 1 mg , 5 mg 20 mg TID oral sildenafil treatment subject PAH .</brief_summary>
	<brief_title>To Assess The Efficacy Safety Of Oral Sildenafil Treatment Pulmonary Arterial Hypertension .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Subjects PAH ( i.e . IPAH secondary connective tissue disease surgical repair ASD , VSD , PDA , aortopulmonary window ) whose baseline six minute walk test distance &gt; /= 100 &lt; /= 450 m. Subjects mean pulmonary artery pressure &gt; /= 25 mmHg pulmonary artery wedge pressure &lt; /= 15 mmHg rest via right heart catheterization perform within 12 week prior randomization . Subjects whose 6 Minute Walk Distance may limit condition PAH relate dyspnoea fatigue , e.g . claudication vascular insufficiency significant arthritis . Subjects currently receive form chronic treatment PAH prostacyclin , PDE5 inhibitor , endothelinreceptor antagonist , nitrate nitric oxide donor ( e.g . arginine supplement , nicorandil ) form , protease inhibitor ritonavir saquinavir , ketoconazole , itraconazole , alpha blocker . Subjects previously receive drug must stop use period least 1 month prior screen , except case bosentan prostacyclin ( 3 month ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>